Brain-specific change in alternative splicing of Tau exon 6 in myotonic dystrophy type 1  by Leroy, Olivier et al.
1762 (2006) 460–467
http://www.elsevier.com/locate/bbaBiochimica et Biophysica ActaBrain-specific change in alternative splicing of Tau exon 6 in
myotonic dystrophy type 1
Olivier Leroy a, Junning Wang b, Claude-Alain Maurage a, Michel Parent c, Thomas Cooper d,
Luc Buée a, Nicolas Sergeant a, Athena Andreadis b, Marie-Laure Caillet-Boudin a,⁎
a INSERM U422, Pl. de Verdun. 59045 Lille Cedex- France
b Shriver Center 200 Trapelo Road Waltham, MA 02452-6319, USA
c Anatomie et cytologie pathologiques, 153 quai Alsace 59500 Douai-France
d Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
Received 16 September 2005; received in revised form 21 November 2005; accepted 1 December 2005
Available online 29 December 2005Abstract
Alternative splicing is altered in myotonic dystrophy of type 1 (DM1), a syndrome caused by an increase of CTG triplet repeats in the 3′
untranslated region of the myotonic dystrophy protein kinase gene. Previously, we reported the preferential skipping of Tau exon 2 in DM1 brains.
In this study, we analyze the alternative splicing of Tau exon 6 which can be inserted in three different forms (c, p and d) depending on the 3′
splice site used. In fact, inclusion of exon 6c decreases in DM1 brains compared to control brains whereas inclusion of 6d increases. Alteration of
exon 6 splicing was not observed in DM1 muscle although this exon was inserted in RNAs from normal muscle and DM1 splicing alterations were
first described in this organ. In contrast, alteration of exon 2 of Tau mRNAwas observed in both muscle and brain. However, co-transfections of a
minigene containing exon 6 with CELF or MBNL1 cDNAs, two splicing factor families suspected to be involved in DM1, showed that they
influence exon 6 splicing. Altogether, these results show the importance of determining all the exons and organs targeted by mis-splicing to
determine the dysregulation mechanisms of mis-splicing in DM1.
Published by Elsevier B.V.Keywords: Tauopathy; Myotonic dystrophy of type 1; Microtubule-associated Tau; Alternative splicing; Muscle; Brain1. Introduction
Myotonic dystrophy of type 1 (DM1) is a multisystemic
disorder characterized by myotonia, progressive weakness,
wasting of skeletal muscle and extramuscular symptoms such as
cataracts, insulin resistance, testicular atrophy, endocrine
dysfunction and mental impairment. The brain-related symp-
toms include mental retardation, sleep disorders, behavioral
changes, alterations in brain structure and cognitive defects [1–
6]. DM1 is caused by the expansion of an unstable CTG repeat
located in the 3′ untranslated region of the myotonic dystrophy
protein kinase gene (DMPK) [7]. DMPK is widely expressed, in
particular in skeletal muscle and heart but also in brain [8,9]. In
DM1, instead of being exported to the cytoplasm, the mutant
DMPK mRNA is retained in multiple discrete foci within the⁎ Corresponding author. Tel.: +33 3 20 62 20 73; fax: +33 3 20 62 20 79.
E-mail address: caillet@lille.inserm.fr (M.-L. Caillet-Boudin).
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doi:10.1016/j.bbadis.2005.12.003nucleus [10]. The clinical features are likely caused by an RNA
mechanism in which the CUG repeats alter cellular functions,
including alternative splicing of various transcripts, among
them cardiac troponin T (cTNT), insulin receptor (IR), muscle-
specific chloride channel (ClC-1) and Tau [11–16].
Members of two protein families, CELF (CUG-BP and
ETR3-like factors) and MBNL (muscleblind-like), are sus-
pected to play a role in the misregulation of alternative splicing
observed in DM1. CELF proteins are CUG-binding proteins
that regulate alternative splicing [17]. MBNL proteins also
regulate splicing, apparently as antagonists to the CELF
proteins [18]. CUG-BP1 levels increase in DM1 muscle
[13,19], whereas MBNL1 protein localizes to the DM1 foci
[16,20,21]. The data are consistent with a mechanism for DM
pathogenesis in which the expanded repeats cause a loss of
MBNL function by sequestration and/or a gain of CELF
activity, leading to the misregulation of alternative splicing of
specific pre-mRNA targets [22].
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[15,16]. In addition to this change, DM1 brains show
neurofibrillary degeneration (NFD) made of the intraneuronal
aggregation of hyperphosphorylated Tau proteins [15,23].
These two pathological entities are common characteristics of
a subset of neurodegenerative diseases called Tauopathies [24].
Tau expression is regulated by complex alternative splicing
[25]. The adult human central nervous system mainly expresses
six Tau RNAs that differ from each other by the inclusion or
exclusion of exons 2, 3 and 10 [26–28]. The inclusion of exon
6, another cassette, was reported in human brain and in non-
neuronal cells [29–31]. In vivo, exon 6 is preferentially
included in retina, spinal cord, and the peripheral nervous
system RNAs which constitutively include exons 2, 3, 4A and
10. For exon 6, three 3′ splice sites were described in humans,
one canonical (c) and two sites (p and d) originally considered
as cryptic [30,32]. They are used in different tissues, particularly
in skeletal muscle and spinal cord [30]. The 6p and 6d variants,
if translated, would result in truncated Tau isoforms that lack the
microtubule-binding domain, whereas isoform 6c contains this
domain. The truncated 6d Tau isoforms have been recently
found in several tissues, including brain and muscle [33].
In DM1, an alteration of inclusion of Tau exon 2 and 10 has
been reported in the brain tissue [15,16]. Splicing of Tau exon 2
in muscle, another tissue where Tau is expressed, have not been
studied in DM1 subjects. Here, we report the pattern of Tau exon
6 splicing in brain and muscle of DM1 patients in comparison to
that of Tau exon 2. This is the first report of a change in Tau exon
6 splicing associated with a human pathology and of a tissue-
specific DM1 mis-splicing. Our results from co-transfections of
COS cells as well as analyses of DM1 brains and glial and
neuronal cell lines suggest that the three splice sites of Tau exon
6 are regulated by distinct trans-regulatory factors. The selection
of the exon 6 3′ splice sites likely implies some members of
MBNL and CELF splicing factor families.
2. Materials and methods
2.1. Brain and muscle tissues
DM1 brain tissue samples were obtained at autopsy of 3 patients aged from
53 to 64 years. These cases were previously described and characterized for Tau
exon 2 splicing and CTG repeats [15]. Two control subjects were included. The
brain tissue was obtained from Department of Neurology, Lille, France, in
accordance with the local ethic committee protocol. Post-mortem delays were
b48 h, and all samples were stored at −80 °C. Cortical brain regions (temporal,
occipital, frontal and parietal regions) were dissected according to Brodmann's
classification.
Skeletal muscles (4 controls and 3 DM1 subjects) were obtained from the
Department of Pathological Anatomy, Lille, France and laboratory of
Pathological Anatomy, Douai France, in accordance with the local ethics
committee. The samples came from biopsies except for one sample, which
corresponded to an autopsy of a DM1 patient whose brain was also analyzed.
2.2. Cell culture
NT2 cells were maintained in OptiMEM medium containing 10% fetal
calf serum, 50 IU/ml penicillin, 50 μg/ml streptomycin and 2 mmol/
l glutamine. NT2 differentiation was performed as described in Ferreira et al.
[34] Briefly, cells were treated with 10 μM retinoic acid (RA) (Sigma, St.
Louis, MO) added in Dulbecco's modified Eagle's medium (DMEM)(Invitrogen) supplemented with 10% fetal calf serum, 2 mM glutamine and
penicillin–Streptomycin for 4–5 weeks. Afterwards, cells were replated at 1/4
dilution and, 2 days later, treated for two additional weeks with a mitotic
inhibitor mix (10 μM 5-fluoro-2′-deoxyuridine, 10 μM uridine, 1 μM
cytosine-B-D-Arabinofuranoside). Finally, after a mild trypsinization protocol,
the cellular population was enriched in neuronal hNT cells.
Human neuroblastoma SKN-SH SY5Y (SY5Y), astrocytoma CCF-STTG1
(CCF) and glioblastoma T98 cells were maintained in DMEM medium
supplemented with 10% fetal calf serum, 50 IU/ml penicillin, 50 μg/ml
streptomycin and 4 mmol/l glutamine. SY5Y cells were differentiated by 1μg
RA treatment for 2 weeks in serum-free medium (DMEM/Ham's F12, 2 mM
glutamine, 50 μg/ml streptomycin, 50 U/ml penicillin, (Sigma), 1× Insulin-
transferrin-Selenium (Invitrogen).
Human neuroblastoma Kelly cells were maintained in RPMI 1640 medium
supplemented with 10% fetal calf serum, 50 IU/ml penicillin, 50 μg/ml
streptomycin and 2 mmol/l glutamine as described in Caillet-Boudin et al. [35].
Monkey kidney (COS) and human epithelial (HeLa) cells were maintained
in DMEM plus 10% fetal calf serum.
2.3. Constructs and transfections
Construct SV6 consists of a 900-kb insert containing Tau exon 6 placed
in the EcoRI site of vector SVIRB [30]. The six members of the CELF
family (CUG-BP1, ETR3, CELF3, CELF4, CELF5 and CELF6) were placed
in pcDNA3.1/His (Invitrogen). MBNL1 isoform 3 in pCMV-SPORT6
(Invitrogen) came from the ATCC cDNA collection and was then placed
into pFLAG-CMV-6b (Sigma). Protein expression was verified by using
monoclonal antibodies against the FLAG or 6× His epitopes (Sigma) on
westerns of crude lysates from cells transfected with each construct. Plasmid
DNA was prepared by Qiagen Tip-50s and introduced into COS cells by
lipofection (LT1, Mirus) 5 μg of SV6 DNA alone or with 5 μg of factor
DNA were introduced into COS cells at ∼30% confluence. Transfection
assays were performed in COS to allow the comparison with ulterior reports
on exon 2 and 3 splicing [30,36–38].
2.4. Reverse transcription and PCR assays
Total RNA was isolated with extraction kits from the following vendors:
from brain and muscle, Promega; from untransfected neuronal and glial cells,
Macherey-Nagel; and from transfected COS cells, by the TRIzol method
(Invitrogen) 48 h post-transfection. Reverse transcription of RNA from
human tissues and untransfected neuroblastoma and glioma cells was carried
out according to the manufacturer's instructions (superscript one-step RT-
PCR kit, Invitrogen) using 1 μg of total RNA. After reverse transcription
(30 min at 55 °C), the reaction mixture was heated to 94 °C for 3 min and
followed by 30–40 PCR cycles with 30 s at 94 °C, 30 s at the optimal
hybridization temperature of each primer pair (see Table 1), 2 min extension
at 72 °C. RT-PCR products were resolved on a 2% (wt/vol) agarose gel
electrophoresis and stained with ethidium bromide. Cloning and sequencing
ascertained the identity of RT-PCR products. The ratio between isoforms was
calculated by scanning the bands using a FluoroImager scanner (Claravision,
France). The values were normalized to an equal quantity of 18S. For RNA
from transfected COS cells, we performed RT-PCR analyses of RNA as
previously described [39] for 25 cycles with primer pairs INS1/INS3 (Table
1). The isoform ratio was calculated by scanning the bands from three
independent transfections using the One-Dscan program and the Scanalytics
IPLab software. The statistical significance of the results was calculated by
the one-way ANOVA method using Sigmastat software.
3. Results
3.1. Exon 6 splicing changes in DM1 brain but not in DM1
muscle
We first analyzed splicing of Tau exon 6 in brain from both
control and DM1 subjects. Using the E4–E7 primers, we mainly
Table 1
Primer pairs used in RT-PCR analyses
Amplified
region
Primers and hybridization temperature
(S=sense, A=antisense, all primers written 5′ to 3′)
No. of
cycles
Possible amplified
products
Tau S: TACGGGTTGGGGGACAGGAAAGAT 35 286 bp→2+3+
E1–E4 A: GGGGTGTCTCCAATGCCTGCTTCT 199 bp→2+3−
Hybridization temperature: 65 °C 112 bp→2–3−
Tau S: GGCTCTGAAACCTCTGATGC 40 443 bp→2+3+6c
E2–E6 A: TTGAGTTTCATCTCCTTTGC 356 bp→2+3−6c
Hybridization temperature: 56 °C 342 bp→2+3+6p
273 bp→2+3+6d
255 bp→2+3−6p
186 bp→2+3−6d
Tau S: GAAGACGAAGCTGCTGGTCA 30 278 bp→6c
E4–E6 A: TTGAGTTTCATCTCCTTTGC 177 bp→6p
Hybridization temperature: 56 °C 108 bp→6d
Tau S: GAAGACGAAGCTGCTGGTCA 35 411 bp→6c
E4–E7 A: TCTTTGGAGCGGGCGGGGTTTTTG 310 bp→6p
Hybridization temperature: 56 °C 241 bp→6d
213 bp→6−
18S S: AAACGGCTACCACATCCAAG 35 250 bp
A: CGCTCCCAAGATCCAACTAC
Hybridization temperature: 58 °C
IR S: CCAAAGACAGACTCTCAGAT 35 167 bp→11+
E10–E12 A: AACATCGCCAAGGGACCTGC 131 bp→11−
Hybridization temperature: 58 °C
SV6/exon 6 S: CAGCTACAGTCGGAAACCATCAGCAAGCAG 25 494 bp→6c
INS1–INS3 A: CACCTCCAGTGCCAAGGTCTGAAGGTCACC 393 bp→6p
Hybridization temperature: 65 °C 324 bp→6d
296 bp→6−
20 nM of primers were used except for 18S primers for which we used only 2 nM for linear amplification at 35 cycles.
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brains. However, low levels of isoform 6c were observed in
control but not in DM1 brains (Fig. 1A). Because Tau 6c, the
main form of exon 6 insertion, was poorly expressed in brain
(about 8% of total Tau transcripts as seen on the histogram of
Fig. 1A), an internal primer was used to detect and quantify the
minor forms 6p and 6d together the 6c form. By using primers
E4–E6, we confirmed the decrease of exon 6c in frontal (F),
temporal (T), parietal (P) and occipital (O) lobes of DM1 brains
(Fig. 1B). This decrease was counterbalanced by an increase of
6d inclusion. The parallel analysis of exons 2, 3 and 6 using Tau
E2–E6 primer pair clearly showed a decrease in both exon 2 and
exon 6c, reflecting the decrease observed by a separate
amplification of each corresponding region (Fig. 1B, C, D).
Modification of the exon 6 splicing pattern in DM1 brains was
not due to a difference in RNA quantity, as shown by the
amplification of 18S RNA.
When we analyzed splicing of Tau exon 6 in skeletal
muscle, no decrease in exon 6c or increase in 6d was
observed in DM1 muscle compared to control whatever the
primer pair used (Fig. 2A). This implies that changes in exon
6 splicing which occur in DM1 is brain specific. In contrast to
exon 6, exon 2 inclusion decreases in DM1 skeletal muscle
(Fig. 2B). Indeed, the forms without exons 2 and 3 are hardly
detected in control muscle but are clearly visible in DM1
samples. As a control of splicing alterations in DM1 muscle
samples, we amplified IR exon 11 (Fig. 2C). As reported
elsewhere, insertion of IR exon 11 is much rarer in DM1 than
in control muscle.Therefore, the DM1 pathological change of Tau alternative
splicing affects exons 2 and 6 in brain but only exon 2 in
skeletal muscle.
3.2. Analysis of exon 6 splicing in neuronal and glial cells
The default in alternative splicing observed for several
transcripts in DM1 results either in nonfunctional truncated
proteins due to a frame shift, as described for ClC-1 [14] or in a
preferential synthesis of the fetal form when the exon splicing is
developmentally regulated, as described for cTNT, IR and Tau
[11,13,15,16]. Interestingly, Tau exon 6 is a particular case.
Indeed, Tau exon 6 is present in both fetal and adult brain and
spliced isoforms resulted from the selection of three 3′ splice
sites, two of which lead to a frame shift. To dissect the cellular
events that regulate the splicing of Tau exon 6, we investigated
the influence of cellular type and neuronal differentiation on the
selection of the three splice sites of exon 6.
Since glial cells are the most abundant cell type in brain and
neurons are the cells where nuclear foci mainly accumulate in
DM1, we analyzed cell lines of glial (CCF-STTG1 and T98)
and neuronal (neuroblastoma Kelly and SK-N-SH SY5Y,
teratocarcinoma NT2) origin. HeLa cells were used as a cell
line that do not originate from the nervous system. For the
second part, we analyzed pro-neuronal cell lines (SY5Y and
NT2) before and after differentiation with RA.
Primer pair E4–E7 detects two main bands in glial and HeLa
cells, which correspond to products 6c and 6- (Fig. 3A). As
shown by the histogram (Fig. 3A), the 6c form is less abundant
Fig. 1. Inclusion of Tau alternative exons 2 and 6 decreases in DM1 brain. The inclusion levels of the two exons were compared in control (Ctrl) and DM1 brain
samples using Tau primer pairs (A) E4–E7, (B) E4–E6, (C) E2–E6 and (D) E1–E4. (E) Amplified 18S, as control for RNA quantity. At the left of each panel, a
diagram shows the identity of the bands amplified by the primer pair indicated. We show the analysis of several areas (T: temporal, F: frontal, O: occipital, P: parietal)
from two control (N1 and N2) and two DM1 patients (case 1 and case 3 correspond to the same patients yet described in Sergeant et al. [14], case 2 analyses (not
shown) gave similar results). Tau mRNAwithout exon 6 is the predominant isoform in brain as seen in panel A. However, species 6c, 6p and 6d are clearly seen in
panels B and C. Inclusion of 6c decreases in DM1 brains for which the ratio shifts from 6c toward 6d. Exon 2 is also decreased in DM1 (panels C and D) as first
reported in Sergeant et al. [14]. At the right of each panel, an histogram illustrates the ratio of the different amplified bands, calculated for the pool of brain areas from
the 3 patients and 2 controls. The values were normalized to an equal quantity of 18S. The statistical significance of the results is indicated by *Pb0.05, **Pb0.01;
***Pb0.001. Neg: RT-PCR in absence of RNAs. L: DNA Ladder.
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being the main amplified band. We also searched for use of
splice sites 6p and 6d with primer pair E4–E6. 6p and 6d are
hardly detected in glial and HeLa cells. These forms were better
amplified in neuronal cells, after differentiation with RA (Fig.
3B). In RA-treated cells, the decrease in 6c levels correlates
with a concurrent increase of the 6p and 6d forms. Hence,
neuronal differentiation strengthens the differences observed in
Tau exon 6 splicing between neuronal cells and non-neuronal
cells (glial and HeLa cells): a decrease of 6c form, an increase of
6p and 6d forms.
3.3. Trans-regulatory factors that are implicated in DM1
regulate the splicing of Tau exon 6
Some members of the MBNL1 and CELF protein families
regulate the splicing of several exons such as cTNT exon 5,
IR exon 11 whose splicing is altered in DM1 [22,25]. It is not
known whether those trans-regulatory factors regulate the
splicing of Tau exon 6. We addressed this question by co-
transfecting COS cells with MBNL1 or CELF familymembers and with an exon 6 minigene (Fig. 4). CELF5
and CELF6 modestly but significantly increase 6c and 6- at
the expense of 6p, the latter more so than the former. The
other five factors (CUG-BP1, ETR3, CELF3, CELF4 and
MBNL1) leave the ratio between exon 6 isoforms practically
unchanged.
4. Discussion
4.1. Splicing of Tau exon 6 is altered in DM1 brains and not in
muscles
A deregulation in splicing occurs in DM1 resulting in
splicing shifts in several transcripts. In particular, mis-splicing
of Tau exon 2 and 10 have been reported in DM1 brains
[15,16]. Up to date, no report has been published about Tau
exon 6 although it is the fourth exon possibly inserted in
cerebral Tau mRNAs. Here, we report Tau exon 6 as a new
target of splicing deregulation in DM1 brain. This is the first
report about a change in splicing of Tau exon 6 in a human
pathology. Exon 6c, the main form of the exon 6 in normal
Fig. 2. Analysis of Tau splicing in control and DM1 muscles. The inclusion
levels of Tau exons 2 and 6c were analyzed in 4 control and 3 DM1 muscle
samples using primer pairs (A) Tau E4–E6, (B) Tau E1–E4 and compared to IR
exon 11 splicing using (C) IR E10–E12. The gels show the results from 3
control and 2 DM but histograms were calculated for the 4 control and 3 DM1
samples.(A) No change is seen in relative ratios of Tau exon 6 splicing products.
(B, C) Both Tau exon 2 and IR exon 11 are suppressed in DM1 muscle. (D)
Amplified 18S, as control for RNA quantity. The values were normalized to an
equal quantity of 18S. The statistical significance of the results is indicated by
*Pb0.05, **Pb0.01; ***Pb0.001. Neg: RT-PCR in absence of RNAs. L: DNA
Ladder.
Fig. 3. Tau exon 6 splicing from endogenous transcripts differs between cell
lines of non-neuronal and neuronal origin. RT-PCR analysis of cellular RNAs
from two glial, three neuronal and HeLa cell lines, using primer pairs (A) E4–E7
and (B) E4–E6. (A) All neuronal cells express a significantly lower level of form
6c versus form 6- compared to glial and HeLa cells. (B) There is a significant
decrease in 6c and an increase in 6p and 6d forms in differentiated neuronal cells
(SY 5Y+RA and hNT) compared to other cell lines. (C) Amplified 18S, as
control for RNA quantity. Histograms illustrate the ratio of the different
amplified bands for each cell line, calculated by scanning the bands from at least
three independent experiments. Notes statistically significant change with
*Pb0.05; ***Pb0.001.
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to control ones. In contrast, the 6d form increases.
Tau is expressed in several tissues, especially in brain
and skeletal muscle, two organs affected by splicing
deregulation in DM1. Therefore, Tau RNAs were good
candidates to determine if the mis-splicing is tissue specific
or similar in both tissues. In fact, the tissue-specificity was
dependent on the exon analyzed. The shift in exon 6
splicing that we observed in DM1 brain does not occur in
DM1 muscle. Thus, the DM1 alteration of exon 6 splicing
is likely brain-specific. In contrast, the preferential exclusion
of Tau exon 2 is clearly detected in both DM1 brain and
muscle [15,16, this paper]. Note that this splicing alteration
of exon 2 in DM1 muscle is intriguing, since Tau aggre-
gates resembling tangles are found in inclusion body myo-
sitis [40,41].
Our results agree with the fact that Tau regulated exons are
known to be independently regulated in terms of both their
expression profile and the details of their regulation [25]. For
instance, Tau exon 2 is absent from fetal brain but constitutes
∼50% of Tau protein in adult brain and is constitutively
included in skeletal muscle. Tau exon 6 is present in fetal brain,
whereas it is a minor isoform in adult brain and becomes
prevalent in muscle. In contrast to exon 2, the splicing of Tauexon 6 is influenced by the flanking exons [30,42, this work].
Finally, exon 2 is regulated primarily by exonic and intronic
silencers and their associated trans-regulatory inhibitors [37,39]
but exon 6 may be primarily regulated by branch point selection
and factor PTB [32]. Therefore, exons 2 and 6 are regulated by a
different set of cis- and trans-regulatory elements. Altogether,
these results suggest that several trans-regulatory factors are
likely altered in DM1.
4.2. Splicing regulation of Tau exon 6
Several non-exclusive hypotheses could explain the tissue
specificity of mis-splicing exon 6c as compared to exon 2.
Indeed, the splicing factors involved could be exon-specific
and/or tissue/cell-specific. The endogenous splicing pattern of
Tau exon 2 and 6, and the effect of overexpression of trans-
regulatory factors on Tau exon 6 splicing were analyzed in
several cell lines.
Fig. 4. CELF and MBNL1 proteins influence splicing of exon 6. The RT-PCR
products come from 1:1 co-transfections of construct SV6 with the indicated
factors in COS cells. The identities of the spliced species are indicated as the %
of exon inclusion that was calculated by scanning the bands from three
independent transfection experiments and measuring their areas using the
OneDscan analysis program. Primer pair: INS1/INS3 (Table 1). Significant
differences are indicated.
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nism. Indeed, the insertion of the exon 2 and exon 6 in cellular
model may be decreased by the overexpression of distinct
CELF or MBNL proteins. For instance, CELF-4 favors the
insertion of Tau exon 2 [37, Andreadis, unpublished results)
whereas CELF -5 and -6 act on exon 6 splicing [this paper].
Then, our data suggest that DM1 splicing change of several
exons (exons 2/3 and 6) on a same transcript could result from
different altered processes. However, none of the CELF
factors or MBNL1 seems to induce a decrease of exon 6c
inclusion or an increase of 6d, the major splicing changes
observed in DM1 brains. In contrast, the two most effective
factors, CELF5 and CELF6, favor the complete inclusion
(form 6c) or exclusion of exon 6 (form 6-) at the expense of
6p. The antagonistic effect of the CELF proteins versus
MBNL1 for exon 6c splicing was not observed, as described
for cTNT and IR transcripts, two other RNA targets of splicing
alteration in DM1 [18].
The hypothesis of tissue-specific factor(s) agrees with a
spatially and temporally controlled expression of various
splicing factors [43]. The major mechanism supposed to
underlie the overall splicing alterations in DM1 supposes a
loss of function of MBNL that is recruited within the nuclear
foci. Although differences in MBNL expression and loss-of-
function due to ribonucleoprotein sequestration do not explain
the distinct results observed for exon 6 in brain and muscle,
MBNL may still play an important role in the control of exon 6
alternative splicing. One can imagine that additional tissue-
specific trans-acting factors are also likely to be involved in the
regulation of exon 6 alternative splicing in the brain and skeletal
muscle, thereby explaining the differences detected.
CELF family is the second splicing factor family suspected
to play a role in DM1 splicing alteration. CELF-4 factor, active
on exon 2 splicing, is expressed in both muscle and brain
whereas CELF-5 and -6, active on exon 6 splicing, are only
expressed in brain [17,21,44]. Furthermore, each of these
factors exists under various alternative splice forms and thespatial distribution and specific role of each isoform must be
considered.
At last, tissues are composed by an heterogenous cell
population and the splicing analysis of tissues then correspond
to a global analysis of splicing from of all cell types. The
analysis of homogenous cell cultures show that different cellular
types have their proper splicing pattern of exon 6 inclusion.
Neuronal cells express a lower level of 6c RNA compared to 6-
form than in non-neuronal cells. Neuronal cells also show
higher ratios of 6p and 6d inclusion compared to glial cells.
Interestingly, inclusion of 6p and 6d at the expense of 6c
expression becomes more pronounced after neuronal differen-
tiation with RA. This shift could have repercussions on Tau
function, since the use of 6p or 6d splice sites creates frame
shifts that produce truncated Tau proteins which lack the
microtubule-binding domain [30,33]. Furthermore, the simul-
taneous expression of the three possible forms of exon 6 mainly
in the differentiated neuronal cells as compared to the non-
neuronal cells also agrees with an in vivo exon 6 splicing
deregulation in neuronal cells, cells mainly affected in DM1
brain [15,16,23]. These data also support the hypothesis of a
connection between expression of exon 6 and neuronal
differentiation [33,45]. According to Luo et al. [45], exon 6c
inhibits neurite extension in RA-differentiated SY5Y cells,
whereas exon 6d is compatible with neuronal differentiation and
neurite extension [33]. A low level of the 6c isoforms may be
needed during the neuronal differentiation process, but higher
levels of 6c may be needed after the final differentiation has
been reached. This is consistent with the fact that isoform 6c is
the most abundant exon 6 product in control adult brain. We are
now investigating if the decrease of 6c in DM1 brain
corresponds to an attempt at neuronal regeneration. Such a
recapitulation of a differentiation program has been described
for DM1 muscle. Indeed, DM1 myoblasts fail to permanently
withdraw from the cell cycle when stimulated to differentiate
[46].
5. Conclusion
In conclusion, these data support that tau splicing is tissue
and cell-specific. It is highly regulated during development and
cell differentiation. Any modification towards this highly
regulated mechanism is likely to be deleterious to several
neurological disorders, the so-called tauopathies. In DM1, both
exons 2 and 6 are mis-regulated although the latter is observed
only in the brain tissue. Overall our data, associated with
recently published results, suggest that several trans-regulatory
elements are likely misregulated in DM1 and a better
fundamental knowledge of the mechanisms regulating the tau
exon 6 splicing could enable the identification of such trans-
regulatory elements.Acknowledgements
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